%0 Journal Article
%A Rusthoven, Chad G
%A Staley, Alyse W
%A Gao, Dexiang
%A Yomo, Shoji
%A Bernhardt, Denise
%A Wandrey, Narine
%A El Shafie, Rami
%A Kraemer, Anna
%A Padilla, Oscar
%A Chiang, Veronica
%A Faramand, Andrew M
%A Palmer, Joshua D
%A Zacharia, Brad E
%A Wegner, Rodney E
%A Hattangadi-Gluth, Jona A
%A Levy, Antonin
%A Bernstein, Kenneth
%A Mathieu, David
%A Cagney, Daniel N
%A Chan, Michael D
%A Grills, Inga S
%A Braunstein, Steve
%A Lee, Cheng-Chia
%A Sheehan, Jason P
%A Kluwe, Christien
%A Patel, Samir
%A Halasz, Lia M
%A Andratschke, Nicolaus
%A Deibert, Christopher P
%A Verma, Vivek
%A Trifiletti, Daniel M
%A Cifarelli, Christopher P
%A Debus, Jürgen
%A Combs, Stephanie E
%A Sato, Yasunori
%A Higuchi, Yoshinori
%A Aoyagi, Kyoko
%A Brown, Paul D
%A Alami, Vida
%A Niranjan, Ajay
%A Lunsford, L Dade
%A Kondziolka, Douglas
%A Camidge, D Ross
%A Kavanagh, Brian D
%A Robin, Tyler P
%A Serizawa, Toru
%A Yamamoto, Masaaki
%T Comparison of First-Line Radiosurgery for Small-Cell and Non-Small Cell Lung Cancer Brain Metastases (Cross-FIRE).
%J Journal of the National Cancer Institute
%V 115
%N 8
%@ 0027-8874
%C Oxford
%I Oxford Univ. Press
%M DKFZ-2023-00885
%P 926-936
%D 2023
%Z 2023 Aug 8;115(8):926-936
%X Historical reservations regarding radiosurgery (SRS) for small-cell-lung-cancer (SCLC) brain metastases (BrM) include concerns for short-interval/diffuse CNS-progression, poor prognoses, and increased neurological mortality specific to SCLC histology. We compared SRS outcomes for SCLC and non-small-cell-lung-cancer (NSCLC) where SRS is well established.Multicenter first-line SRS outcomes for SCLC and NSCLC from 2000-2022 were retrospectively collected (N=892-SCLC/N=4,785-NSCLC). Data from the prospective JLGK0901 SRS trial were analyzed as a comparison cohort (N=98-SCLC/N=794-NSCLC). OS and CNS-progression were analyzed using Cox-Proportional-Hazard and Fine-Gray models, respectively, with multivariable (MV) adjustment (including age/sex/performance-status/year/extracranial disease/BrM-number/BrM-volume). Mutation-stratified analyses were performed in propensity score-matched (PSM) retrospective cohorts of EGFR/ALK-positive-NSCLC, mutation-negative-NSCLC, and SCLC.OS was superior with NSCLC over SCLC in the retrospective dataset (median-OS, 10.5 vs 8.6 months, MV-p<0.001) and JLGK0901. Hazard estimates for first CNS-progression favoring NSCLC were similar in both datasets but reached significance in the retrospective dataset only (MV-HR:0.82 [95
%K brain metastases (Other)
%K non-small cell lung cancer (NSCLC) (Other)
%K small-cell lung cancer (SCLC) (Other)
%K stereotactic radiosurgery (SRS) (Other)
%K whole brain radiation therapy (WBRT) (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37142267
%R 10.1093/jnci/djad073
%U https://inrepo02.dkfz.de/record/275797